Bottom line
They target different biology. Evidence that a product changes a biomarker is not the same as evidence of improved function or longevity.
| Question | Ergothioneine | NAD+ precursors |
|---|---|---|
| Primary biological context | Diet-derived compound with specialized cellular uptake | Precursors or pathway compounds intended to influence NAD+ availability |
| Human evidence | Small trials and observational signals | More biomarker trials for some precursors; clinical-outcome evidence remains mixed and context-specific |
| Food sources | Mushrooms and selected foods | Niacin-related precursors occur in diet; products use distinct forms |
| Typical supplement amounts | Often measured in milligrams | Commonly hundreds of milligrams, depending on form |
| Research maturity | Emerging | Larger commercial and human-trial footprint |
| Main research interest | Cellular stress, aging, cognition | Energy metabolism, NAD+ biology, aging |
How to interpret this comparison
- NAD+, NR, NMN and niacin are not synonyms.
- A dose comparison across unrelated compounds is meaningless.
- Combination claims require direct evidence; mechanism stacking is not proof.